Epistemwww.epistem.co.uk TICKER: EHP EXCHANGE: L
This is a UK-based biotechnology company specialised in adult epithelial stem cell operating, providing pre-clinical efficacy drug development services (fee-for-service basis) to the biopharmaceutical industry for the development of innovative therapeutics addressing oncology, gastroenterology, wound healing and dermatology therapeutic areas; a range of non-invasive biomarkers (personalised medicine) for drug development for the measurement of drug-induced changes in gene expression from individual hair plucked from patients undergoing cancer treatment; commenced Beta testing of GeneDrive a novel molecular diagnostic for sexually transmitted diseases (STDs). Additionally the company is developing its own proprietary novel therapeutics to control cell production by researching the key regulators (proteins/peptides) of epithelial cells. Epistem has signed collaboration agreements with sector giants Sanofi-Aventis for biomarker discovery and clinical support, and with Novartis for the development of novel drug discovery programme. Additionally, they have a long-standing programme with the US Government Biodefence programme.
R&D collaboration agreement with Novartis is a transformational event in company's development
The Company maintains its strong reputation for pursuing commercially viable growth via up-front cash payments and 2 year funding
Epistem achieves the rare status of a profitable UK biotech company
Foreign buyers gorging on UK stocks
Document can be downloaded here: UK plc ‘going for a song’
Being a shareholder in a company that receives a juicy takeover offer is a marvellous feeling. Something that many fortunate investors have experienced over the past 3 years. Thanks to a spate of M&A bids by deep pocketed overseas buyers – partly triggered by the June 2016 Brexit result, which sent the £ tumbling and adversely affected the FTSE.
Consequently today, given this trend is unlikely to end anytime soon, we’ve highlighted 30 possible acquisition ideas in the attached research paper. Spilt equally between large and smallcap stocks – covering a broad selection of industries.
What’s more we believe most of these businesses are underpinned by strong fundamentals and substantial upside in the event of predatory interest.
According to Factset Mergerstat/BVR, the average bid premium paid for such deals between 2004-14 was 30% – with the figure trending upwards since the global financial crisis.
Happy investing. Published 27th August 2019